Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atrovent, Spiriva Safety To Be Tracked In Pharmacy Active Surveillance Pilot

Executive Summary

An active drug surveillance system pilot, directed by the Critical Path Institute (C-Path), will track safety and efficacy information for the chronic obstructive pulmonary disorder therapies Atrovent and Spiriva

You may also be interested in...



Public/Private Partnership Is Best Vehicle For Active Rx Surveillance System

An active drug safety surveillance system is "doable," and would cost in the tens of millions of dollars, GlaxoSmithKline Chief Medical Officer Ronald Krall said during a recent Institute of Medicine symposium on the future of drug safety

Public/Private Partnership Is Best Vehicle For Active Rx Surveillance System

An active drug safety surveillance system is "doable," and would cost in the tens of millions of dollars, GlaxoSmithKline Chief Medical Officer Ronald Krall said during a recent Institute of Medicine symposium on the future of drug safety

One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA

One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs

Related Content

UsernamePublicRestriction

Register

PS046774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel